CLAIMS

1. Use of drospirenone in the manufacture of a contraceptive for a female patient affected with obesity, wherein drospirenone is a sole contraceptive ingredient comprised in a daily active dosage unit in an amount of at least 3 mg, wherein the said daily active dosage unit is comprised within a contraceptive kit comprising one or more packaging units wherein each packaging unit comprises 21 to 28 daily active dosage units and wherein :

a. the amount of drospirenone in each daily active dosage unit is at least 3 mg without estrogen, and

b. each daily active dosage unit comprises drospirenone in a form such that:

i. no more than 50% of the drospirenone initially present in the said daily active dosage unit is dissolved within 30 minutes and
ii. at least 50% of the said drospirenone is dissolved in a time range from 3 hours to 4 hours,

when the daily active dosage unit is subjected to an in vitro dissolution test according to the USP XXIII Paddle Method, the percentages of drospirenone being related to the amount of drospirenone initially present in the said daily active dosage unit.

2. The use according to claim 1, wherein the female patient has a BMI of 30 kg/m^2 or greater.

3. The use according to claim 1, wherein the amount of drospirenone in each daily active unit dosage ranges from about 3.5 mg to 4.5 mg.

4. The use according to claim 2, wherein the one or more packaging units further comprise from 1 to 7 daily dosage units of a pharmaceutically acceptable placebo.

5. The use according to claim 2, wherein each packaging unit comprises 24 daily active dosage units.

6. The use according to claim 4, wherein each packaging unit comprises 4 daily placebo dosage units.

7. The use according to any one of claims 1 to 6, wherein drospirenone is in a crystalline form.

8. The use according to any one of claims 1 to 7, wherein drospirenone is in a non-micronized form.

9. The use according to any one of claims 1 to 8, wherein drospirenone has a d_{50} of less than 70 μm.

10. The use according to any one of claims claim 1 to 9, wherein drospirenone in a particle form has a specific surface area from about 2,000 cm^2/g to about 8,500 cm^2/g.